Home Health Lung cancer, yes European to target drug by form that affects young non-smokers

Lung cancer, yes European to target drug by form that affects young non-smokers

by admin

A drug indicated for the advanced form of lung cancer that affects approximately 37,500 people worldwide each year and is often diagnosed in patients younger than the average age of people diagnosed with lung cancer, and in people without a strong smoking habit. It is pralsetinib, conditionally approved – because studies are still ongoing – by the European Commission for the monotherapy treatment of adult patients with advanced stage non-small cell lung cancer (NSCLC) positive for fusion of the REarranged during Transfection gene. (RET) not previously treated with a RET inhibitor. Pralsetinib is the first and only target treatment approved in the European Union for the first-line treatment of patients with advanced NSCLC fusion positive for the RET gene.

“With the approval of pralsetinib by the European Commission, patients with RET fusion positive non-small cell lung cancer will have access to the first authorized target therapy in Europe for the first-line treatment of this type of cancer. pulmonary – commented Filippo de Marinis, Director of the Thoracic Oncology Division of the European Institute of Oncology (IEO) in Milan – Therefore, the need to be able to carry out a complete genomic profiling already at the diagnosis is becoming increasingly important, to address patients, often young people and non-smokers, towards the most appropriate first-line treatment for RET-positive lung cancer. “The data on which the Commission relied are those of the ongoing Phase I / II ARROW study, in which pralsetinib has shown a lasting response and was generally well tolerated, with a low rate of definitive discontinuation of treatment.

See also  Delta: Bmj, infected vaccinated and not with the same viral load - Medicine

RET, ALK, ROS1 are mutations that can be found in NSCLC for which targeted treatments are now available. Which can only be assured if patients are subjected to effective and accurate diagnostic tests. In addition to non-small cell cancer, RET alterations are oncogenic drivers for other types of cancer, such as thyroid cancers. Pralsetinib has been shown to act in different types of solid tumors, indicating an agnostic action potential, i.e. independent of the type of cancer, including thyroid. Based on the results obtained, the United States Food and Drug Administration has approved the drug both for the treatment of adult patients with RET-positive metastatic NSCLC and for the treatment of adult and pediatric patients 12 years of age and older who have advanced thyroid tumors positive for RET alterations. The European agency (EMA) will also soon receive registration applications for RET fusion positive thyroid and medullary RET mutated thyroid cancers.


0 comment

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy